Drug Shortage Report for EPIRUBICIN FOR INJECTION
| Report ID | 133445 |
| Drug Identification Number | 02324091 |
| Brand name | EPIRUBICIN FOR INJECTION |
| Common or Proper name | EPIRUBICIN INJECTION 2MG/ML |
| Company Name | TEVA CANADA LIMITED |
| Market Status | MARKETED |
| Active Ingredient(s) | EPIRUBICIN HYDROCHLORIDE |
| Strength(s) | 2MG |
| Dosage form(s) | SOLUTION |
| Route of administration | INTRAVENOUS INTRAVENOUS |
| Packaging size | 100ml |
| ATC code | L01DB |
| ATC description | CYTOTOXIC ANTIBIOTICS AND RELATED SUBSTANCES |
| Reason for shortage | Disruption of the manufacture of the drug. |
| Anticipated start date | |
| Actual start date | 2021-02-03 |
| Estimated end date | 2021-03-31 |
| Actual end date | 2021-03-10 |
| Shortage status | Resolved |
| Updated date | 2021-03-11 |
| Company comments | |
| Health Canada comments | |
| Tier 3 Status | No |
| Contact Address | 30 NOVOPHARM COURT TORONTO, ONTARIO CANADA M1B 2K9 |
| Company contact information |
Version History
Click on "Compare" below to view the full report history and compare to other versions.
| Version Number | Date Updated | Language | |
|---|---|---|---|
| v4 | 2021-03-11 | French | Compare |
| v3 | 2021-03-11 | English | Compare |
| v2 | 2021-02-05 | French | Compare |
| v1 | 2021-02-05 | English | Compare |
Showing 1 to 4 of 4